$148.00/50µL $248.00/100µL
50 µL | $148.00 |
100 µL | $248.00 |
Product name: | LATS1/2 rabbit pAb |
Reactivity: | Human;Mouse |
Alternative Names: | LATS1; WARTS; Serine/threonine-protein kinase LATS1; Large tumor suppressor homolog 1; WARTS protein kinase; h-warts; LATS2; KPM; Serine/threonine-protein kinase LATS2; Kinase phosphorylated during mitosis protein; Large tumor suppressor ho |
Source: | Rabbit |
Dilutions: | Western Blot: 1/500 - 1/2000. IHC-p: 1:100-300 ELISA: 1/20000. IF 1:100-300 Not yet tested in other applications. |
Immunogen: | The antiserum was produced against synthesized peptide derived from human LATS1/2. AA range:1041-1090 |
Storage: | -20°C/1 year |
Clonality: | Polyclonal |
Isotype: | IgG |
Concentration: | 1 mg/ml |
Observed Band: | 130-140kD |
GeneID: | 9113/26524 |
Human Swiss-Prot No: | O95835/Q9NRM7 |
Cellular localization: | Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, spindle . Midbody . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Localizes to the centrosomes throughout interphase but migrates to the mitotic apparatus, including spindle pole bodies, mitotic spindle, and midbody, during mitosis. . |
Background: | The protein encoded by this gene is a putative serine/threonine kinase that localizes to the mitotic apparatus and complexes with cell cycle controller CDC2 kinase in early mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with late prophase phosphorylation remaining through metaphase. The N-terminal region of the protein binds CDC2 to form a complex showing reduced H1 histone kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In addition, the C-terminal kinase domain binds to its own N-terminal region, suggesting potential negative regulation through interference with complex formation via intramolecular binding. Biochemical and genetic data suggest a role as a tumor suppressor. This is supported by studies in knockout mice showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a high sensitivity to carcinogenic treatmen |